Recurrence after liver transplantation for hepatocellular carcinoma

Annals of Surgery

Volumn 265, Issue 3, 2017, Pages 557-564

  Halazun, Karim J ^a,b   Najjar, Marc ^b   Abdelmessih, Rita M ^b   Samstein, Benjamin ^a,b   Griesemer, Adam D ^b   Guarrera, James V ^b   Kato, Tomoaki ^b   Verna, Elizabeth C ^b   Emond, Jean C ^b   Brown, Robert S ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Department of Medicine   (United States)

Author keywords

hepatocellular carcinoma; liver transplantation; Milan criteria; outcomes; predictive models; recurrence

Indexed keywords

ADULT; ARTICLE; CANCER RECURRENCE; CLINICAL OUTCOME; COHORT ANALYSIS; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; POSTOPERATIVE PERIOD; PREDICTIVE VALUE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; RECURRENT DISEASE; RISK ASSESSMENT; ADVERSE EFFECTS; AGED; CANCER STAGING; CARCINOMA, HEPATOCELLULAR; DISEASE FREE SURVIVAL; FACTUAL DATABASE; GRAFT REJECTION; GRAFT SURVIVAL; KAPLAN MEIER METHOD; LIVER NEOPLASMS; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROCEDURES; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC; SURVIVAL ANALYSIS; THERAPY; TUMOR INVASION; TUMOR RECURRENCE; UNIVERSITY HOSPITAL;

ACADEMIC MEDICAL CENTERS; ADULT; AGED; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; DATABASES, FACTUAL; DISEASE-FREE SURVIVAL; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; ROC CURVE; SURVIVAL ANALYSIS;

EID: 84986222581     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0000000000001966     Document Type: Article

References (45)

1. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996; 334: 693-699
2. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001; 33: 1394-1403
3. Onaca N, Davis GL, Goldstein RM, et al. Expanded criteria for liver transplantation in patients with hepatocellular carcinoma: a report from the International Registry of Hepatic Tumors in Liver Transplantation. Liver Trasnplant. 2007; 13: 391-399
4. Ito T, Takada Y, Ueda M, et al. Expansion of selection criteria for patients with hepatocellular carcinoma in living donor liver transplantation. Liver Transpl. 2007; 13: 1637-1644
5. Dvorchik I1, Schwartz M, Fiel MI, et al. Fractional allelic imbalance could allow for the development of an equitable transplant selection policy for patients with hepatocellular carcinoma. Liver Transpl. 2008; 14: 443-450
6. Nault JC, De Reyniès A, Villanueva A, et al. A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. Gastroenterology. 2013; 145: 176-178
7. Xu JF, Liu XY. PIVKA-II is an independent prognostic factor for overall survival of HCC patients and maybe associated with epithelial-mesenchymal transition. J Hepatol. 2015; 63: 1040-1041
8. Meguro M1, Mizuguchi T1, Nishidate T1, et al. Prognostic roles of preoperative a-fetoprotein and des-g-carboxy prothrombin in hepatocellular carcinoma patients. World J Gastroenterol. 2015; 21: 4933-4945
9. Hiraoka A, Ishimaru Y, Kawasaki H, et al. Tumor markers AFP, AFP-L3, and DCP in hepatocellular carcinoma refractory to transcatheter arterial chemoembolization. Oncology. 2015; 89: 167-174
10. Templeton AJ, McNamara MG, S ? eruga B, et al. Prognostic role of neutrophilto-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014; 106. dju124
11. Halazun KJ, Aldoori A, Malik HZ, et al. Elevated preoperative neutrophil to lymphocyte ratio predicts survival following hepatic resection for colorectal liver metastases. Eur J Surg Oncol. 2008; 34: 55-60
12. Malik HZ, Prasad KR, Halazun KJ, et al. Preoperative prognostic score for predicting survival after hepatic resection for colorectal liver metastases. Ann Surg. 2007; 246: 806-814
13. Gomez D, Farid S, Malik HZ, et al. Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma. World J Surg. 2008; 32: 1757-1762
14. Halazun KJ, Hardy MA, Rana AA, et al. Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma. Ann Surg. 2009; 250: 141-151
15. Bertuzzo VR, Cescon M, Ravaioli M, et al. Analysis of factors affecting recurrence of hepatocellular carcinoma after liver transplantation with a special focus on inflammation markers. Transplantation. 2011; 91: 1279-1285
16. Wang GY, Yang Y, Li H, et al. A scoring model based on neutrophil to lymphocyte ratio predicts recurrence of HBV-associated hepatocellular carcinoma after liver transplantation. PLoS One. 2011; 6: e25295
17. Motomura T, Shirabe K, Mano Y, et al. Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment. J Hepatol. 2013; 58: 58-64
18. Lai Q, Castro Santa E, Rico Juri JM, et al. Neutrophil and platelet-tolymphocyte ratio as new predictors of dropout and recurrence after liver transplantation for hepatocellular cancer. Transpl Int. 2014; 27: 32-41
19. Xiao GQI, Yang JY, Yan LN. Combined Hangzhou criteria with neutrophillymphocyte ratio is superior to other criteria in selecting liver transplantation candidates with HBV-related hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2015; 14: 588-595
20. Sherman M. Alphafetoprotein: an obituary. J Hepatol. 2001; 34: 603-605
21. DuBay D1, Sandroussi C, Sandhu L, et al. Liver transplantation for advanced hepatocellular carcinoma using poor tumor differentiation on biopsy as an exclusion criterion. Ann Surg. 2011; 253: 166-172
22. Tyson GL, Duan Z, Kramer JR, et al. Level of a-fetoprotein predicts mortality among patients with hepatitis C-related hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2011; 9: 989-994
23. Vibert E1, Azoulay D, Hoti E, et al. Progression of alphafetoprotein before liver transplantation for hepatocellular carcinomain cirrhotic patients: a critical factor. Am J Transplant. 2010; 10: 129-137
24. Toso C, Meeberg G, Hernandez-Alejandro R, et al. Kneteman NM total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: a prospective validation. Hepatology. 2015; 62: 158-165
25. Duvoux C1, Roudot-Thoraval F, Decaens T, et al. Liver Transplantation French Study Group. Liver transplantation for hepatocellular carcinoma: a model including (-fetoprotein improves the performance of Milan criteria. Gastroenterology. 2012; 143: 986-994
26. Furukawa H1, Shimamura T, Suzuki T, et al. Liver transplantation for hepatocellular carcinoma: the Japanese experience. J Hepatobiliary Pancreat Sci. 2010; 17(5): 533-538
27. Halazun K, El-Najjar A, Zaretsky J, Brubaker W, Guarrera JV, Samstein B, et al. Recurrence after liver transplantation for HCC-a new MORAL to the story. Am J Transpl; 2013. Conference: 13th Annual State of the Art Winter Symposium of theAmerican Society of Transplant Surgeons: January 2013, P77
28. Lee JH, Cho Y, Kim HY, et al. Serum tumor markers provide refined prognostication in selecting liver transplantation candidate for hepatocellular carcinoma patients beyond the Milan criteria. Ann Surg. 2016; 263: 842-850
29. Cescon M1, Bertuzzo VRI, Ercolani GI, et al. Liver transplantation for hepatocellular carcinoma: role of inflammatory and immunological state on recurrence and prognosis. World J Gastroenterol. 2013; 19: 9174-9182
30. Gomez D, Farid S, Malik HZ, et al. Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma. World J Surg. 2008; 32: 1757-1762
31. Peng SYI, Chen WJ, Lai PL, et al. Hsu HC High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53, and betacatenin mutations. Int J Cancer. 2004; 112: 44-50
32. Jeng YMI, Chang CC, Hu FC, et al. RNA-binding protein insulin-like growth factor II mRNA-binding protein 3 expression promotes tumor invasion and predicts early recurrence and poor prognosis in hepatocellular carcinoma. Hepatology. 2008; 48: 1118-1127
33. Bavry AAI, Kumbhani DJ, Gong Y, et al. Simple integer risk score to determine prognosis of patients with hypertension and chronic stable coronary artery disease. J Am Heart Assoc. 2013; 2: e000205
34. Motomura T1, Shirabe K, Mano Y, et al. Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment. J Hepatol. 2013; 58: 58-64
35. Kuang DM, Peng C, Zhao Q, et al. Tumor-activated monocytes promote expansion of IL-17-producing CD8+ T cells in hepatocellular carcinoma patients. J Immunol. 2010; 185: 1544-1549
36. Kuang DM, Zhao Q, Wu Y, et al. Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma. J Hepatol. 2011; 54: 948-955
37. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004; 4: 71-78
38. Harper A, Edwards E, Washburn WK, et al. An early look at the OPTN explant pathology form data. Liver Transpl. 2016; 22: 757-764. doi: 10.1002/lt.24441
39. Nissen NNI, Menon V, Bresee C, et al. Recurrent hepatocellular carcinoma after liver transplant: identifying the high-risk patient. HPB (Oxford). 2011; 13: 626-632
40. Ferreiro AO, Vazquez-Millán MA, López FS, et al. Everolimus-based immunosuppression in patients with hepatocellular carcinoma at high risk of recurrence after liver transplantation: a case series. Transplant Proc. 2014; 46: 3496-3501
41. Ercolani G1, Vetrone G, Grazi GL, et al. Intrahepatic cholangiocarcinoma: primary liver resection and aggressive multimodal treatment of recurrence significantly prolong survival. Ann Surg. 2010; 252: 107-114
42. Schnelldorfer T, Ware AL, Sarr MG, et al. Farnell MB Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible? Ann Surg. 2008; 247: 456-462
43. Halazun KJ, Patzer RE, Rana AA, et al. Standing the test of time: outcomes of a decade of prioritizing patients with hepatocellular carcinoma, results of the UNOS natural geographic experiment. Hepatology. 2014; 60: 1957-1962
44. Pawlik TM, Gleisner AL, Anders RA, et al. Preoperative assessment of hepatocellular carcinoma tumor grade using needle biopsy: implications for transplant eligibility. Ann Surg. 2007; 245: 435-442
45. Silva MAI, Hegab B, Hyde C, et al. Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut. 2008; 57: 1592-1596